What Анжелик Treats: Main Uses and Benefits

The combination medicine Angeliq (drospirenone/estradiol) is commonly used to provide continuous, stable hormone replacement for postmenopausal women with an intact uterus, focusing on symptomatic relief and relevant long-term protective benefits. The applications of this therapy span three key therapeutic domains.

---

Symptom Management and Therapeutic Domains

This therapy is relevant for managing symptom clusters that may become intense or disruptive, addressing distressing effects of the menopausal transition such as hot flashes, intense night sweats, and symptoms related to urogenital atrophy. These symptoms often include vaginal dryness, irritation, and painful intercourse (dyspareunia).

The benefit is the support it provides in helping ease the overall symptom burden, contributing to comfort during sleep and assisting with maintaining functional stability.

“This treatment generally supports women during episodes of heightened discomfort by providing supportive relief when symptoms interfere with routine activities.”

Essential Benefits and Clinical Context

Beyond immediate discomfort, the treatment is relevant for women at a high risk of future fractures who require support for bone density maintenance. It offers an important protective benefit against accelerated bone loss, helping to support long-term skeletal health and stability. This medicine is primarily applied in clinical settings that involve acute or unstable symptom patterns and is considered relevant for easing challenging symptoms associated with hormonal deficiency.

Quick Fact: Relief for Vasomotor Symptoms The medicine is commonly used to help manage pronounced symptoms related to systemic imbalance, such as moderate to severe hot flashes.

Regulatory References

1. NHS Guidance on Hormone Replacement Therapy

Angeliq (drospirenone/estradiol) is an estrogen-progestogen combination with specific regulatory criteria defining its permissible use. Eligibility is primarily restricted to postmenopausal women who have an intact uterus, as the progestogen component is included solely to mitigate the risk of endometrial overgrowth in this population. Women who have had a hysterectomy are generally not recommended to use this combination.

Populations for Whom Use is Contraindicated

Official labeling strictly prohibits the use of Angeliq in women with certain conditions, including:

• Thromboembolic History: Active or a history of arterial (stroke, myocardial infarction) or venous (DVT, PE) thromboembolic disease.
• Oncological History: Known, suspected, or a history of breast cancer or any other estrogen-dependent neoplasia.
• Organ Dysfunction: Women with severe renal disease, hepatic impairment or disease, or adrenal insufficiency. This restriction relates to the drospirenone component’s impact on potassium levels.
• Other Prohibitions: Undiagnosed abnormal genital bleeding or known thrombophilic disorders.

Age and Physiological Status Limitations

• Pediatric/Adolescent: The medicine is not indicated for children and adolescents, as its safety and efficacy have not been established in this age group.
• Older Adults (ge 65 years): Use is not indicated for the prevention of dementia and has been associated with an increased risk of probable dementia in this age group.
• Pregnancy and Lactation: Angeliq is contraindicated during known or suspected pregnancy, and is not recommended during lactation.

This section outlines documented interaction information based strictly on authoritative governmental regulatory documents. The product's interaction profile is primarily defined by the two hormonal components, estradiol and drospirenone.

Interactions Affecting Hormone Levels

The metabolism of the estradiol component may be altered by other medicines that affect the CYP3A4 enzyme system. Concurrent use with strong or moderate CYP3A4 inhibitors (such as certain antifungal or HIV/HCV protease inhibitor medications, or grapefruit juice) may increase the plasma concentration of the hormones. Conversely, co-administration with CYP3A4 inducers (such as certain antiepileptic drugs, Rifampicin, or the herbal product St. John's wort) may decrease the estrogen concentration, potentially reducing its effectiveness.

Interactions Affecting Serum Potassium

Drospirenone has anti-mineralocorticoid activity, which may lead to an increase in serum potassium concentration. The official labeling specifies a warning against using this drug with other medicines that have the potential to increase serum potassium, including:

• Potassium-sparing diuretics (e.g., spironolactone)
• ACE inhibitors and Angiotensin-II receptor antagonists
• NSAIDs or heparin

Patients with predisposing conditions for hyperkalemia (e.g., renal impairment, adrenal insufficiency) require careful consideration. Monitoring serum potassium levels during the first month of treatment is advised for high-risk patients taking a strong CYP3A4 inhibitor concomitantly and long-term. Additionally, use of tobacco while on this medication significantly increases the risk for serious cardiovascular events.

Анжелик is a continuous combined hormonal product containing estradiol and drospirenone. Its mechanism of action involves interaction with multiple intracellular steroid receptors in target tissues.

Estradiol, an estrogen, functions as an agonist at the Estrogen Receptor (ER), primarily ER-alpha and ER-beta, located in the nucleus of responsive cells. Upon binding, the activated ER-complex translocates to the DNA, modifying the transcription of estrogen-responsive genes. System-level physiological modulation involves changes in vascular tone, thermoregulatory centers, and the maintenance of epithelial tissue structure in the urogenital tract.

Drospirenone, a synthetic progestin, acts as an agonist at the Progesterone Receptor (PR). In the uterus, this PR activation induces secretory transformation of the endometrium, counteracting the proliferative effects mediated by estrogen. Additionally, drospirenone exhibits antagonistic activity at both the Mineralocorticoid Receptor (MR) and the Androgen Receptor (AR), modulating the systemic effects of aldosterone and androgens, respectively. The anti-mineralocorticoid action leads to increased renal excretion of sodium and water, influencing the renin-angiotensin-aldosterone system (RAAS) and plasma volume.

Administration Guidelines: Use of Angeliq

The usage of Angeliq (drospirenone and estradiol) follows a continuous, fixed-dose pattern. The medicine is administered via the oral route as a film-coated tablet.

---

Administration Scope

Instruction	Detail
Route of Administration	Oral administration of film-coated tablets.
Dosing Schedule	One 0.25 mg / 0.5 mg or 0.5 mg / 1 mg tablet taken once daily.
Timing in relation to meals	May be taken irrespective of food intake.
Preparation Requirements	Tablets must be swallowed whole with some liquid; they are not intended to be crushed or split.
Missed-Dose Rules	If a tablet is missed by more than 24 hours, the missed tablet should not be taken, and the regimen should be resumed by taking the next scheduled tablet at the regular time.

---

Instruction Classifications

Classification	Detail
Administration method type	Oral
Frequency pattern	Daily and Continuous
Use-context constraints	Use the lowest effective dose for the shortest duration consistent with treatment goals. Treatment necessity must be periodically re-evaluated.

---

Resulting Procedural Structure

Step sequence:

• Start the continuous therapy at any time if not currently on HRT, or after completing a prior sequential/cyclic cycle.
• Take one tablet once daily, at the same time each day, swallowing it whole.
• Continue daily intake, immediately proceeding to the next 28-day pack without a treatment-free interval.

This regimen defines a continuous oral administration protocol, mandating stable hormone delivery through consistent, uninterrupted, once-daily intake. The instructions guide proper initiation, tablet handling, and protocol for missed doses.

Research evidence / Overview of studies for Анжелик (Angeliq)

The available research evidence for the combination of drospirenone and estradiol is derived primarily from structured Randomized Controlled Trials (RCTs). These studies were designed to explore whether the medicine's use was associated with changes in specific symptoms associated with the postmenopausal period and to evaluate the role of the progestogen component in women who still have a uterus. Research focuses on defined outcomes, with findings describing patterns observed in the studies, rather than providing guarantees of individual results.

---

Evidence for Use in Managing Vasomotor Symptoms

Clinical trials primarily used short-term, placebo-controlled RCTs to study the medicine’s use in postmenopausal women with moderate to severe hot flashes and night sweats. Studies monitored the occurrence of hot flashes; trials reported that the measured frequency was lower in the active group compared to the placebo group over the assessment period. Research examined whether differences were measurable in symptoms like vulvar and vaginal atrophy, with findings contributing to understanding symptom patterns.

The primary efficacy research generally has limited follow-up durations, typically focusing on the initial several months of use. This means that long-term outcomes and the sustained pattern of symptom control are not fully characterized in these trials.

---

Evidence for Use in Bone Mineral Density Maintenance

Research has explored whether the medicine's use was associated with changes in bone health metrics for the prevention of postmenopausal osteoporosis in women at risk of fractures. Studies monitored Bone Mineral Density (BMD) at key skeletal sites over medium-term durations, typically up to two years.

Findings described that the measured change in BMD was less pronounced or reversed in the active treatment group compared to the patterns observed in the placebo group. BMD change is often studied as a surrogate measure in this area of research. Data are still emerging regarding fracture reduction specific to this combination.

---

Research Gaps and Areas of Uncertainty

While the evidence base relies on RCTs, direct comparative evidence is limited regarding the performance of this specific combination against all other available low-dose continuous combined hormone therapy products. Furthermore, results apply only to the populations studied, which were typically healthy postmenopausal women in the early phases of the post-menopause period. This means data for certain groups, such as women with specific complex comorbidities, remain insufficient in the core trials. Research highlights what is known, but it does not offer individual predictions on response.

Common questions about Анжелик (FAQ)

Q: How long does it take for this medication to start working for hot flashes and night sweats?

Studies described in official regulatory documents indicate that relief of menopausal symptoms, such as hot flashes and night sweats, was observed during the first few weeks of treatment in clinical trials. Individual response patterns may vary, but this pattern of response was noted in clinical trials.

Q: What kind of blood or lab tests should I get before starting this medicine?

Regulatory documents describe that a medical professional should perform a thorough medical and gynaecological examination, which typically includes the breasts, and that personal and family medical history is usually reviewed. In cases where liver health is a concern, official guidance indicates that liver function tests are discussed for evaluation before and periodically during therapy.

Q: Will this medicine cause me to gain or lose weight?

According to the official product information, weight changes are listed as a possible adverse reaction. It is descriptively reported that an increase in weight was noted as one of the common reasons for discontinuing the medicine in clinical trials.

Q: Is this medicine suitable for women who have had a premature or surgical menopause at a young age?

Official documents from regulatory bodies indicate that this medication is approved to address moderate to severe symptoms that arise due to menopause. This medication is indicated for symptoms that occur due to menopause, including those associated with premature menopause.

Q: Do I have to take this medicine at the exact same time every day?

Official prescribing instructions indicate that one tablet is administered once daily. While the core requirement is daily intake, patient information describes taking the tablet at the same time each day to promote consistency and adherence to the regimen.

Q: Does this medication affect mood or sleep?

Clinical trials documented certain effects related to mood and nervous system function. Adverse reactions reported include emotional lability (changes in mood) and irritability. Additionally, official documents mention possible changes in sleep patterns as an effect observed during the studies.

How to Store and Dispose of Angeliq

Angeliq tablets must be stored at room temperature, specifically maintained between 20 C and 25 C (68 F to 77 F). The medicine must be kept in a cool, dry place and protected from heat, moisture, and direct light. Storage must not exceed 30 C (86 F).

Handling and Protection Rules

It is prohibited to refrigerate or freeze the tablets. The medication must be kept in its original container or a tightly closed pack until use. Do not use the medicine after the expiry date on the packaging. The product must be stored out of the reach of children.

Disposal of Unused Medicine

Outdated or unused Angeliq should not be discarded in household trash or flushed down the toilet. Disposal of the medicine must be conducted in a manner that follows local requirements for pharmaceutical waste.